Skip to main content
placeholder image

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2013

Citation


  • Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N., De Souza, P. L., . . . Ryan, C. J. (2013). Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).. Journal of Clinical Oncology, 31(15_suppl), 5009. doi:10.1200/jco.2013.31.15_suppl.5009

Web Of Science Accession Number


Start Page


  • 5009

End Page


  • 5009

Volume


  • 31

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2013

Citation


  • Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N., De Souza, P. L., . . . Ryan, C. J. (2013). Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).. Journal of Clinical Oncology, 31(15_suppl), 5009. doi:10.1200/jco.2013.31.15_suppl.5009

Web Of Science Accession Number


Start Page


  • 5009

End Page


  • 5009

Volume


  • 31

Issue


  • 15_suppl

Place Of Publication